
Not actual size
(15 mm x 8 mm)What is BIKTARVY?
BIKTARVY is a complete HIV-1 treatment that combines 3 powerful medicines into 1 small pill, taken once a day with or without food.
BIKTARVY should not be taken with other HIV-1 medicines.
Gilead is committed to helping those living with HIV access their medications. If you need support affording your medication, we may be able to help. Get Financial Support.
Not actual size
(15 mm x 8 mm)BIKTARVY is a complete HIV-1 treatment that combines 3 powerful medicines into 1 small pill, taken once a day with or without food.
BIKTARVY should not be taken with other HIV-1 medicines.
BIKTARVY is a prescription medicine for adults and children with HIV-1 who weigh at least 55 lbs and are either:
†For adults and children replacing their current regimen, their healthcare provider must determine if they meet certain requirements, including having an undetectable viral load (less than 50 copies/mL).
BIKTARVY does not cure HIV-1 or AIDS. HIV-1 is the virus that causes AIDS.
Whether you’re starting HIV treatment for the first time or switching, ask your healthcare provider about the most prescribed* HIV treatment and if it’s right for you.
Built to Start Fast
The 3 powerful medicines in BIKTARVY were designed to attack the virus right away and to work together to lower the amount of HIV in your blood to undetectable levels.
According to the U.S. Department of Health and Human Services (DHHS), many patients can get to undetectable in as quickly as 8 to 24 weeks, when taking their treatment as prescribed. Some people are even able to start treatment the same day as diagnosis.
The 3 powerful medicines in BIKTARVY work quickly to fight the virus.
Whether you’re starting treatment or replacing your current HIV-1 treatment, BIKTARVY can help you reach important HIV-1 health goals.
Starting BIKTARVY:
Both 3-year and 5-year clinical study timepoints showed that most adults new to treatment taking BIKTARVY every day reached and stayed undetectable. Undetectable is when the amount of virus in your blood is below the level that can be measured in a lab test (less than 50 copies/mL).
BIKTARVY can help increase the number of CD4 T-cells in your blood. T-cells are an important part of your immune system because they help your body fight infections.
Switching to BIKTARVY:
BIKTARVY can help adults stay undetectable and maintain your CD4 T-cell count. Before taking BIKTARVY, your healthcare provider must determine that you meet certain requirements.
Starting or switching your HIV-1 treatment is an important decision. Your healthcare provider should always work with you to decide what medicine makes sense.
BIKTARVY was evaluated in 4 clinical trials, involving more than 2,400 adults living with HIV.
Results showed that BIKTARVY works in a diverse group of adults, regardless of age, sex, race, viral load, or CD4 T-cell count.
‡The other treatments were TRIUMEQ® (abacavir, dolutegravir, lamivudine) or DESCOVY® (emtricitabine, tenofovir alafenamide) + TIVICAY® (dolutegravir).
§The continued treatments were TRIUMEQ (abacavir, dolutegravir, lamivudine) or a combination of either EPZICOM® (abacavir, lamivudine) or TRUVADA® (emtricitabine, tenofovir disoproxil fumarate) + atazanavir or darunavir (with cobicistat or ritonavir).
BIKTARVY may cause serious side effects:
Do not take BIKTARVY if you take:
Serious side effects of BIKTARVY may also include:
The most common side effects of BIKTARVY in clinical studies were diarrhea (6%), nausea (6%), and headache (5%). Tell your healthcare provider if you have any side effects that bother you or don’t go away.
It’s important to take your treatment as prescribed, because low levels of medicine in your blood may make it easier for the HIV virus to mutate, or change. Some mutations can cause drug resistance, which means your medicine may stop working and make the virus harder to treat.
A medicine’s barrier to resistance refers to how well it works, even when the virus has mutated. When a medicine has a high barrier to resistance, it means the medicine may still work even if the virus has mutated.
Taking a treatment that has a high barrier to resistance, like BIKTARVY, and taking your medication every day can help prevent drug resistance.
Zero adults new to treatment developed drug resistance to BIKTARVY through 5 years of clinical trials.
Talk to your healthcare provider about why resistance matters.
Download the BIKTARVY patient brochure for more information.
GET PATIENT BROCHURE (PDF)Learn how you may be eligible to get help affording your Gilead medication.
GET FINANCIAL SUPPORTBIKTARVY is a complete,
BIKTARVY does not cure
BIKTARVY may cause serious side effects:
Do not take BIKTARVY if you take:
Serious side effects of BIKTARVY may also include:
The most common side effects of BIKTARVY in clinical studies were diarrhea (6%), nausea (6%), and headache (5%). Tell your healthcare provider if you have any side effects that bother you or don’t go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑10881‑800‑FDA‑1088.
Please see Important Facts about BIKTARVY, including important warnings. >
By following this link, you are now leaving BIKTARVY.com. This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site's content or your use of the site.